The role of liver fructose-1,6-bisphosphatase in regulating appetite and adiposity

Diabetes

Volumn 61, Issue 5, 2012, Pages 1122-1132

  Visinoni, Sherley ^a   Khalid, Nurul Fathiah Izzati ^a   Joannides, Christos N ^a   Shulkes, Arthur ^a   Yim, Mildred ^a   Whitehead, Jon ^b   Tiganis, Tony ^c   Lamont, Benjamin J ^a   Favaloro, Jenny M ^a   Proietto, Joseph ^a   Andrikopoulos, Sofianos ^a   Fam, Barbara C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 BETA HYDROXYBUTYRATE KETONE; AGOUTI RELATED PROTEIN; CHOLECYSTOKININ; FATTY ACID; FRUCTOSE BISPHOSPHATASE; HEXOSAMINE; HYDROXYBUTYRIC ACID; LEPTIN; NEUROPEPTIDE Y; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; ENZYME INHIBITION; FATTY ACID OXIDATION; FEMALE; FOOD INTAKE; MALE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; SATIETY; VAGOTOMY;

ADIPOSITY; AGOUTI-RELATED PROTEIN; ANIMALS; APPETITE; CHOLECYSTOKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; FATTY ACIDS; FEMALE; FRUCTOSE-BISPHOSPHATASE; GENE EXPRESSION REGULATION; HUMANS; HYDROXYBUTYRATES; KETONE BODIES; LEPTIN; LIVER; MALE; MICE; MICE, TRANSGENIC; NEUROPEPTIDE Y; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS;

EID: 84860547618     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1511     Document Type: Article

References (49)

1. Peters JC. Combating obesity: challenges and choices. Obes Res 2003;11 (Suppl.):7S-11S (Pubitemid 41127402)
2. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000;404:661-671 (Pubitemid 30205071)
3. Jambor de Sousa UL, Arnold M, Langhans W, Geary N, Leonhardt M. Caprylic acid infusion acts in the liver to decrease food intake in rats. Physiol Behav 2006;87:388-395 (Pubitemid 43188836)
4. Jambor de Sousa UL, Benthem L, Arsenijevic D, et al. Hepatic-portal oleic acid inhibits feeding more potently than hepatic-portal caprylic acid in rats. Physiol Behav 2006;89:329-334
5. Langhans W, Wiesenreiter F, Scharrer E. Different effects of subcutaneous D,L-3-hydroxybutyrate and acetoacetate injections on food intake in rats. Physiol Behav 1983;31:483-486 (Pubitemid 13018476)
6. Rawson NE, Blum H, Osbakken MD, Friedman MI. Hepatic phosphate trapping, decreased ATP, and increased feeding after 2,5-anhydro-D-mannitol. Am J Physiol 1994;266:R112-R117
7. Russek M. Participation of hepatic glucoreceptors in the control of intake of food. Nature 1963;197:79-80
8. Horn CC, Friedman MI. Metabolic inhibition increases feeding and brain Fos-like immunoreactivity as a function of diet. Am J Physiol 1998;275:R448-R459
9. Horn CC, Friedman MI. Methyl palmoxirate increases eating behavior and brain Fos-like immunoreactivity in rats. Brain Res 1998;781:8-14 (Pubitemid 28082843)
10. Andrikopoulos S, Proietto J. The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1995;38:1389-1396
11. Song S, Andrikopoulos S, Filippis C, Thorburn AW, Khan D, Proietto J. Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. Am J Physiol Endocrinol Metab 2001;281:E275-E282
12. Visinoni S, Fam BC, Blair A, et al. Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver. Am J Physiol Endocrinol Metab 2008;295:E1132-E1141
13. Fam BC, Morris MJ, Hansen MJ, et al. Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity. Diabetes Obes Metab 2007;9:840-852 (Pubitemid 47555205)
14. Mangiafico SP, Lim SH, Neoh S, et al. A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion. J Endocrinol 2011;210:335-347
15. Rana K, Fam BC, Clarke MV, Pang TP, Zajac JD, Maclean HE. Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. Am J Physiol Endocrinol Metab 2011;301:E767-E778
16. Wong N, Fam BC, Cempako GR, et al. Deficiency in interferon-gamma results in reduced body weight and better glucose tolerance in mice. Endocrinology 2011;152:3690-3699
17. Tordoff MG, Rawson N, Friedman MI. 2,5-anhydro-D-mannitol acts in liver to initiate feeding. Am J Physiol 1991;261:R283-R288
18. Lai C, Gum RJ, Daly M, et al. Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase. Bioorg Med Chem Lett 2006;16:1807-1810 (Pubitemid 43267355)
19. von Geldern TW, Lai C, Gum RJ, et al. Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1,6-bisphosphatase with a distinct binding mode. Bioorg Med Chem Lett 2006;16:1811-1815 (Pubitemid 43267356)
20. Lo CM, Zhang DM, Pearson K, et al. Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am J Physiol Regul Integr Comp Physiol 2007;293:R1490-R1494 (Pubitemid 47535766)
21. Chearskul S, Delbridge E, Shulkes A, Proietto J, Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr 2008;87:1238-1246 (Pubitemid 351679764)
22. Horn CC, Ji H, Friedman MI. Etomoxir, a fatty acid oxidation inhibitor, increases food intake and reduces hepatic energy status in rats. Physiol Behav 2004;81:157-162 (Pubitemid 38430052)
23. Andrikopoulos S, Rosella G, Kaczmarczyk SJ, Zajac JD, Proietto J. Impaired regulation of hepatic fructose-1,6-biphosphatase in the New Zealand Obese mouse: an acquired defect. Metabolism 1996;45:622-626 (Pubitemid 26146116)
24. Konrad RJ, Tolar JF, Hale JE, Knierman MD, Becker GW, Kudlow JE. Purification of the O-glycosylated protein p135 and identification as O-GlcNAc transferase. Biochem Biophys Res Commun 2001;288:1136-1140 (Pubitemid 33131718)
25. Zraika S, Dunlop M, Proietto J, Andrikopoulos S. The hexosamine biosynthesis pathway regulates insulin secretion via protein glycosylation in mouse islets. Arch Biochem Biophys 2002;405:275-279 (Pubitemid 35191742)
26. Steinberg GR, Watt MJ, Fam BC, et al. Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 2006;147:3906-3914 (Pubitemid 44079396)
27. Lamont BJ, Visinoni S, Fam BC, et al. Expression of human fructose-1, 6-bisphosphatase in the liver of transgenic mice results in increased glycerol gluconeogenesis. Endocrinology 2006;147:2764-2772 (Pubitemid 43764613)
28. Weis BC, Cowan AT, Brown N, Foster DW, McGarry JD. Use of a selective inhibitor of liver carnitine palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J Biol Chem 1994;269:26443-26448
29. Andrikopoulos S, Rosella G, Gaskin E, et al. Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse model of NIDDM. Diabetes 1993;42:1731-1736 (Pubitemid 23346409)
30. Kebede M, Favaloro J, Gunton JE, et al. Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function. Diabetes 2008;57:1887-1895
31. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998;393:684-688 (Pubitemid 28289657)
32. Housley MP, Rodgers JT, Udeshi ND, et al. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 2008;283:16283-16292
33. Song S, Zhang Y, Ma K, et al. Peroxisomal proliferator activated receptor gamma coactivator (PGC-1alpha) stimulates carnitine palmitoyltransferase I (CPT-Ialpha) through the first intron. Biochim Biophys Acta 2004;1679:164-173
34. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38:550-557 (Pubitemid 19125601)
35. Erion MD, van Poelje PD, Dang Q, et al. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci USA 2005;102:7970-7975 (Pubitemid 40781047)
36. van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 2006;55:1747-1754 (Pubitemid 44324128)
37. Veroni MC, Proietto J, Larkins RG. Evolution of insulin resistance in New Zealand obese mice. Diabetes 1991;40:1480-1487
38. Baker L, Winegrad AI. Fasting hypoglycaemia and metabolic acidosis associated with deficiency of hepatic fructose-1,6-diphosphatase activity. Lancet 1970;2:13-16
39. el-Maghrabi MR, Lange AJ, Jiang W, et al. Human fructose-1,6- bisphosphatase gene (FBP1): exon-intron organization, localization to chromosome bands 9q22.2-q22.3, and mutation screening in subjects with fructose-1,6-bisphosphatase deficiency. Genomics 1995;27:520-525
40. Faiyaz-Ul-Haque M, Al-Owain M, Al-Dayel F, et al. Novel FBP1 gene mutations in Arab patients with fructose-1,6-bisphosphatase deficiency. Eur J Pediatr 2009;168:1467-1471
41. Kikawa Y, Inuzuka M, Jin BY, et al. Identification of genetic mutations in Japanese patients with fructose-1,6-bisphosphatase deficiency. Am J Hum Genet 1997;61:852-861 (Pubitemid 27418459)
42. Matsuura T, Chinen Y, Arashiro R, et al. Two newly identified genomic mutations in a Japanese female patient with fructose-1,6-bisphosphatase (FBPase) deficiency. Mol Genet Metab 2002;76:207-210 (Pubitemid 35034553)
43. Moon S, Kim JH, Han JH, et al. Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis. Metabolism 2011;60:107-113
44. Date Y, Shimbara T, Koda S, et al. Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metab 2006;4:323-331 (Pubitemid 44430917)
45. Reidelberger RD, Hernandez J, Fritzsch B, Hulce M. Abdominal vagal mediation of the satiety effects of CCK in rats. Am J Physiol Regul Integr Comp Physiol 2004;286:R1005-R1012 (Pubitemid 38661387)
46. Napal L, Marrero PF, Haro D. An intronic peroxisome proliferator- activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A. J Mol Biol 2005;354:751-759 (Pubitemid 41735500)
47. Hawkins M, Angelov I, Liu R, Barzilai N, Rossetti L. The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem 1997;272:4889-4895 (Pubitemid 27090037)
48. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 1997;99: 2173-2182 (Pubitemid 27203773)
49. Festuccia WT, Blanchard PG, Turcotte V, et al. Depot-specific effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism. J Lipid Res 2009;50:1185-1194